Completed

Paracetamol Effect on Oxidative Stress and Renal Function in Severe Falciparum Malaria With Intravascular Haemolysis: A Randomised Controlled Clinical Trial

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Paracetamol

+ No Paracetamol

Drug
Who is being recruted

Vector Borne Diseases+4

+ Mosquito-Borne Diseases

+ Infections

Over 12 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: July 2012
See protocol details

Summary

Principal SponsorUniversity of Oxford
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 10, 2012

Actual date on which the first participant was enrolled.

Mortality in severe malaria remains \~15% despite the best available parasiticidal antimalarial therapy, intravenous artesunate. Adjunctive therapies in combination with anti-parasitic drugs have the potential to improve outcomes. However, currently there are no proven adjunctive therapies for the treatment of severe malaria, which can improve case-fatality when used in combination with anti-parasitic drugs. This research proposal focuses on exploring if paracetamol prevents renal dysfunction caused by free haemoglobin induced oxidative damage in severe malaria. Blackwater fever epidemiology As early as the 1800s, blackwater fever complicating severe malaria caused by Plasmodium falciparum was recognized as an important cause of morbidity and mortality, with a 25-30% mean mortality rate. The etiology and pathogenesis is poorly understood but it is characterized by massive intravascular haemolysis and passage of black or red urine, which can lead to renal impairment and death. This manifestation was linked to quinine therapy as its occurrence nearly disappeared during the chloroquine era from 1950 to 1980. Since 1990, the resurgence in the number of cases noted in both malaria-free and malarious areas in non-immune and immune individuals has generated renewed interest into this manifestation of severe malaria. The largest malaria clinical trials report blackwater fever incidences of 7% and 4% in Asian adult patients with severe malaria treated with artesunate and quinine, respectively and 4% in African children treated with either drug. The prevalence of blackwater fever in Chittagong, Bangladesh was recently determined in a pilot study to be 15% with associated renal failure and mortality rates of 42.9% and 14.2% respectively. Blackwater fever pathogenesis Although the exact mechanism linking falciparum malaria and blackwater fever is uncertain, numerous explanations have been suggested. It has been proposed to occur in 4 specific circumstances: (1) in case patients with G6PD deficiency with or without malaria who take oxidant drugs (primaquine) (2) in case patients with G6PD deficiency and malaria untreated and treated with quinine (3) when patients (normal G6PD) with severe malaria are treated with quinine (4) when people exposed to malaria self-medicate with quinine or related amino-alcohol drugs. However, new circumstances of blackwater fever have emerged, occurring in patients with normal G6PD levels with severe malaria who have received artesunate rather than quinine. Role of oxidative stress and free haem The fundamental characteristic of blackwater fever is the presence of massive haemolysis of both infected and uninfected erythrocytes and release of free haemoglobin. The free haem is highly cytotoxic, and an important scavenger of nitric oxide, promoting endothelial damage and is proposed to be involved in the pathogenesis of renal injury and cerebral malaria. When the degree of intravascular haemolysis exceeds the capacity of plasma haptoglobin to bind the haemoglobin released from red blood cells, free haemoglobin is then filtered by the glomeruli and enters the renal tubules. In a series of renal biopsies, fine and coarse haemoglobin granules are present in the proximal tubules, while haemoglobin casts and granular casts predominate in the distal and collecting tubules in patients with blackwater fever and intravascular haemolysis. This classic theory of renal damage by tubular precipitation is challenged by recent findings of reversing oxidative properties of free haem can prevent renal damage. The free haemoglobin present is pathogenic as the ferrous haem can be oxidized to the ferric state (FeIII) subsequently conferring peroxidase activity to the haemoglobin. Consequently, the haemoglobin can reduce hydroperoxides, such as hydrogen peroxide (H2O2) and lipid hydroperoxides, which generate the ferryl state (FeIV=O) of haemoglobin and a globin protein radical. Haem Fe(III) protein + H2O2 --> haem \[Fe(IV)=O\] protein• + H+ + H2O The ferryl haem and protein radical can then generate lipid radicals by oxidation of free and phospholipid-esterified unsaturated fatty acids. The arachidonic side chains of membrane phospholipids are particularly vulnerable to this free radical-mediated damage in the complex cascade of lipid oxidation leading to the generation of F2-isoprostanes (F2-IsoPs) and isofurans (IsoFs). Evidence suggests that F2-isoPs generated by the haemoprotein-catalyzed oxidation of lipids are responsible for the oxidative damage and vasoconstriction associated with renal injury in the setting of hemolytic disorders and rhabdomyolysis. Paracetamol and oxidative stress A novel mechanism of paracetamol was recently demonstrated, showing that paracetamol acts as a potent inhibitor of haemoprotein-catalyzed lipid peroxidation by reducing ferryl haem to its less toxic ferric state and quenching globin radicals. This effect is enhanced 14-fold in an acidic milieu. In a recent proof of concept trial, paracetamol at therapeutic levels was shown to significantly decrease oxidant injury in the kidney, improve renal function and reduce renal damage by inhibiting the haemoprotein-catalyzed lipid peroxidation, mediated by redox cycling of the haem moiety of myoglobin, in a rat model of rhabdomyolysis-induced renal injury. Rationale Since adults with severe malaria and blackwater fever associated with haemolysis demonstrate increased concentrations of cell-free haemoglobin, severe acidosis and urinary F2-IsoPs, the investigators hypothesize that this novel inhibitory mechanism of paracetamol may provide renal protection in this population by reducing the haemoprotein-induced lipid peroxidation. As there is currently no consensus that exists concerning adequate medical treatment for blackwater fever, the potential application of this safe and extensively used drug would be of great benefit. Proposed activities The main activity proposed is a randomised open label controlled study of paracetamol in patients with severe falciparum malaria to assess its modulating effect on renal function and oxidative stress.

Official TitleParacetamol Effect on Oxidative Stress and Renal Function in Severe Falciparum Malaria With Intravascular Haemolysis: A Randomised Controlled Clinical Trial
NCT01641289
Principal SponsorUniversity of Oxford
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

62 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 12 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Vector Borne DiseasesMosquito-Borne DiseasesInfectionsMalariaParasitic DiseasesProtozoan InfectionsMalaria, Falciparum

Criteria

4 inclusion criteria required to participate
Patient age >12 years

Presence of severe or moderately severe P. falciparum malaria, with and without blackwater fever, confirmed by positive blood smear with asexual forms of P. falciparum

Temperature >38 degrees Celsius on admission or fever during the preceding 24hours

Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Bangla and copies provided to the patient.

6 exclusion criteria prevent from participating
Patient or relatives unable or unwilling to give informed consent

History of chronic liver disease

History of alcohol use (>3drinks per day)

Contraindication or allergy to paracetamol or artesunate therapy

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
\>50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate

Group II

Active Comparator
No paracetamol + Intravenous Artesunate * If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Suspended

Chittagong Medical College Hospital

Chittagong, BangladeshOpen Chittagong Medical College Hospital in Google Maps
Suspended

Ramu Upazilla Health Complex

Rāmu, Bangladesh
Completed2 Study Centers